Stocks and Investing Stocks and Investing
Fri, November 3, 2017

David Risinger Maintained (TEVA) at Sell with Decreased Target to $7 on, Nov 3rd, 2017


Published on 2024-10-26 00:27:54 - WOPRAI, David Risinger
  Print publication without navigation


David Risinger of Morgan Stanley, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Sell with Decreased Target from $14 to $7 on, Nov 3rd, 2017.

David has made no other calls on TEVA in the last 4 months.



There are 8 other peers that have a rating on TEVA. Out of the 8 peers that are also analyzing TEVA, 5 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Douglas Tsao of "Barclays" Maintained at Hold with Decreased Target to $19 on, Friday, October 20th, 2017
  • Liav Abraham of "Citigroup" Downgraded from Strong Buy to Hold on, Wednesday, August 16th, 2017
  • Aaron Gal of "Bernstein" Downgraded from Buy to Hold on, Friday, August 4th, 2017
  • Tyler Van Buren of "Cowen & Co." Downgraded from Buy to Hold on, Friday, August 4th, 2017
  • Derek Archila of "Oppenheimer" Downgraded from Buy to Hold on, Thursday, August 3rd, 2017


These are the ratings of the 3 analyists that currently disagree with David


  • Tim Chiang of "BTIG" Upgraded from Hold to Strong Buy and Held Target at $24 on, Monday, September 11th, 2017
  • Vamil Divan of "JMP Securities" Maintained at Sell with Increased Target to $14 on, Wednesday, September 6th, 2017
  • Randall Stanicky of "RBC Capital" Downgraded from Buy to Sell on, Friday, August 4th, 2017
Contributing Sources